When was Dermavant founded?

Dermavant was founded in 2016 and raised its 1st funding round 5 years after it was founded.

Where is Dermavant located?

Dermavant is headquartered in Phoenix, United States. It is registered at 3780 KILROY AIRPORT WAY SUITE 250, LONG BEACH, United States, 90806, CA.

How many employees does Dermavant have?

As of Apr 30, 2026, the latest employee count at Dermavant is 143.

Is Dermavant a funded company?

Dermavant is a funded company, having raised a total of $160M across 2 funding rounds to date. The company's 1st funding round was a $***** Series D round, raised on Jun 08, 2021.

When was the latest funding round of Dermavant?

Dermavant's latest funding was a $***** Conventional Debt round on Jun 08, 2021, with participation from 0 investor. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $172M in funding in 2026 to date.

Where does Dermavant rank among its competitors?

Dermavant ranks 5th amongst 173 active competitors, of which 42 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Shaperon, which secured $5.82M in Apr, 2026.

Who are the top competitors of Dermavant?

Dermavant's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Among them, Shaperon secured the most recent funding round in April, 2026.

Dermavant - 2026 Company Profile, Team, Funding & Competitors

Q: Is Dermavant an acquired company?

Dermavant got acquired by Organon on Sep 18, 2024.

Company Details

Developer of small molecule-based therapeutics for the treatment of inflammatory skin diseases. The company's lead product candidate DMVT-505 is a therapeutic AhR modulating agent inhibiting several proinflammatory factors used for the treatment of psoriasis, atopic dermatitis. Other products of the company include DMVT-502 against atopic dermatitis and vitiligo which is Phase 1 clinical trial, DMVT-504 against primary focal hyperhidrosis.

Website: dermavant.com
Social
Email ID: *****@dermavant.com
Phone Number: +1 **********
Registered Address: 3780 KILROY AIRPORT WAY SUITE 250, LONG BEACH, United States, 90806, CA

Key Metrics

Founded Year

2016

Location

Phoenix, United States

Stage

Acquired

Total Funding

$160M in 2 rounds

Latest Funding Round

Conventional Debt, Jun 08, 2021, $*****

Investors

Marathon Asset Management & 1 more

Ranked

5^th among 173 active competitors

Employee Count

143 as on Apr 30, 2026

Similar Companies

Revance Therapeutics & 229 more

Exit Details

Acquired by Organon (Sep 18, 2024)

View Dermavant's full profile

Dermavant is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DERMAVANT SCIENCES, INC. CIN: 001t000000x91vuAAA , United States, Active	Dec 14, 2022	-	-	-
Dermavant Sciences Gmbh CIN: 1274437 , Switzerland, Active	May 01, 2024	-	-	-

Dermavant got acquired by Organon on Sep 18, 2024 at an acquisition amount of $*****.

Click here to take a look at Dermavant's acquisition in detail

Dermavant has raised a total funding of $160M over 2 rounds. Its first funding round was on Jun 08, 2021. Dermavant has 2 institutional investors.

Here is the list of recent funding rounds of Dermavant:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 08, 2021	4650554	Conventional Debt	9131228	9878637	3470163	7549083
Jun 08, 2021	3707299	Series D	2845967	9553690	Marathon Asset Management & 1 more	2383747

Access funding benchmarks and valuations. Sign up today!

View details of Dermavant's funding rounds and investors

Dermavant's employee count trend

Dermavant has 143 employees as of Apr 26. Here is Dermavant's employee count trend over the years:

Uncover Dermavant's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dermavant include Revance Therapeutics, Lineage Cell Therapeutics and Evolus. Here is the list of Top 10 competitors of Dermavant, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	66/100
3rd	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	62/100
4th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
5th	Dermavant 2016, Phoenix (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases	$160M	Marathon Asset Management, NovaQuest Capital Management ... Read more	61/100
6th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
7th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	59/100
8th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
9th	Shaperon 2008, Seoul (South Korea), Public	Developer of therapies for multiple diseases	-	Samsung Securities, Mirae Asset & 6 others	56/100
10th	AiVita Biomedical 2016, Irvine (United States), Series B	Developer of dendritic cell immunotherapy for cancer and markets stem cells based facial serum for skin care	$46M	California Technology Ventures, Ci:z Investment ... & 5 others	55/100